Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeros Tech Regulatory News (XSG)

Share Price Information for Xeros Tech (XSG)

Share Price is delayed by 15 minutes
Get Live Data
1.425    -0.075 (-5.00%)
Bid:
1.35
Ask:
1.50
Spread: 0.15 (11.111%)
Market Cap: £12.28m
XSG Live PriceLast checked at - London Stock Exchange

Intraday Xeros Tech Share Chart

Directorate Change

13 Jan 2020 12:00

RNS Number : 6134Z
Xeros Technology Group plc
13 January 2020
 

Xeros Technology Group plc

Board Changes

 

Xeros Technology Group plc (AIM: XSG, "the Company", "the Group" or "Xeros"), the developer and provider of water saving and filtration technologies with multiple commercial applications, is pleased to announce today the appointment of Klaas de Boer as Chairman. At the same time, David Armfield (current Chairman) moves to the position of Senior Independent Director.

 

Klaas de Boer, aged 54, is the Managing Partner of Entrepreneurs Fund Management LLP, a partnership whose sole activity is to advise Entrepreneurs Fund General Partner Limited (a Jersey incorporated company) being the general partner of Entrepreneurs Fund LP ("Entrepreneurs Fund"). Entrepreneurs Fund owns 224,253,474 ordinary shares in the Company, representing 28.6% of the total voting rights. The fund is one of a number of enterprises owned by the COFRA group.

 

Klaas de Boer also holds positions on the boards of Vasopharm (Würzburg, D), specialising in novel therapeutics for the treatment of cerebro and cardiovascular diseases; General Fusion (Vancouver, CND), a private nuclear fusion company which has raised over $200MM for developing commercial fusion power; and SmartKem (Manchester, UK), which focuses on organic semiconductor inks for flexible transistor layers (OTFT) driving various types of displays.

 

Commenting on these changes, Mark Nichols, Chief Executive commented:

 

"We are very pleased to announce the appointment of Klaas de Boer as Chairman of our Board. Klaas brings a wealth of experience in the funding and commercialisation of innovative products and important business connections including those within the COFRA group.

 

"We are also delighted that David Armfield has taken up the role of Senior Independent Director. Myself and the Board thank David for his Chairmanship during 2019, a period when the Company achieved a number of major milestones and materially completed its migration to a license based business."

 

Enquiries:

 

Xeros Technology Group plc

Mark Nichols, Chief Executive Officer

Paul Denney, Chief Financial Officer

 

Tel: 0114 321 6328

 

finnCap Limited (Nominated Adviser, Broker)

Julian Blunt / Teddy Whiley, Corporate Finance

Andrew Burdis, ECM

 

Tel: 020 7220 0570

 

AIM Rules for Companies Schedule 2 (g) information

Klaas de Boer, holds or has held the following directorships/partnerships in the five years preceding his appointment to the Xeros Technology Group Plc Board.

Current Directorships & Partnerships:

Entrepreneurs Fund Management LLP (Partner)

Entrepreneurs Fund Management Services Ltd

Entrepreneurs Fund LP (Partner)

Tsjukemar Ltd

Park Road Associates Ltd

General Fusion Inc.

SmartKem Ltd

Vasopharm GmbH

Oomph Wellness Ltd

Previous Directorships & Partnerships (held within the last 5 years):

GZPaul Investments Ltd

The New Motion BV

Optinose Inc

2010 Perfect Vision AG

Lifeline Scientific Inc

Heliocentris Energy Solutions AG

Prosonix Ltd

n-Tec AS

 

Mr De Boer, as a representative of Entrepeneurs Fund, was a member of the supervisory board of Heliocentris Energy Solutions AG, a German incorporated company listed on the Frankfurt Stock Exchange. Entrepreneurs Fund had provided approximately €7.7m in equity funding and €400,000 in loans to Heliocentris and its group companies (including FutureE Fuel Cell Solutions GmbH which Heliocentris acquired in 2014) between 2008 and 2016. Heliocentris was put into liquidation in December 2016. To date Entrepeneurs Fund has recovered nothing (nor does it expect to) from the insolvency process, which remains ongoing.

Entrepreneurs Fund owns 224,253,474 ordinary shares ("Ordinary Shares") in the Company, representing 28.6 per cent of the total voting rights of Xeros. As managing partner of Entrepreneurs Fund Management LLP Mr. De Boer indirectly provides advice to the general partner of Entrepreneurs Fund in relation to the shares but he does not control the voting interests.

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

Notes to Editors

 

Xeros Technology Group plc is a platform technology Group that is transforming water intensive industrial and commercial processes.

Xeros' patented XOrbTM technologies significantly reduce the amount of water used in the washing or dyeing of soft substrates such as garments and fabrics. They enable the remaining water to become far more efficient and effective in either affixing or removing molecules, the result being improvements in economic, operational, product and sustainability outcomes. The Group is applying its technology in the fields of cleaning, tanning and textiles.

Xeros' XDrumTM technology is a patented, simple, low cost machine drum design which enables XOrbs to be introduced into and subsequently removed from process cycles in Xeros' chosen markets. The design enables rotating drum machine Original Equipment Manufacturers ("OEMs") in the fields of garment manufacture and cleaning, the ability to make simple and low cost changes in their production lines to incorporate the Company's XOrbTM technology.

The Group has signed multiple agreements to develop and license its XDrumTM and XOrbTM products in major commercial and domestic markets.

XFiltraTM is a patented in-machine filtration technology which is designed to prevent harmful micro-plastics generated by washing cycles from being released into the aquacycle. Plastics released from synthetic clothing during washing cycles is one of the single largest sources of primary micro-plastic pollution. For more information, please visit - http://www.xerostech.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOABBGDBXDBDGGX
Date   Source Headline
28th Apr 20267:00 amRNSFull Year Results 2025
21st Apr 20267:00 amRNSNotice of Results and Online Presentation
5th Mar 20267:00 amRNSPurchase Order ahead of European Launch of XF3
11th Feb 202610:39 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSBoard Change
27th Jan 20267:00 amRNSTrading Update
7th Jan 20262:52 pmRNSTR-1 First Equity
2nd Jan 202611:46 amRNSBlock listing Interim Review
11th Dec 20251:06 pmRNSTR-1 Entrepreneurs Fund
2nd Dec 20254:48 pmRNSTR-1 Lombard Odier
2nd Dec 20252:26 pmRNSTR-1 Dowgate
2nd Dec 202511:10 amRNSTR-1 Maven
28th Nov 202511:02 amRNSResults of General Meeting and Director Dealings
27th Nov 202512:28 pmRNSResult of Follow-on Subscription and TVR
26th Nov 20254:44 pmRNSTR-1 Spreadex
11th Nov 20251:14 pmRNSResult of Retail Offer
7th Nov 202510:15 amRNSResult of Fundraising
7th Nov 20257:00 amRNSRetail Offer
6th Nov 20256:32 pmRNSProposed Fundraise
24th Oct 20253:07 pmRNSBlock listing Interim Review
14th Oct 20255:11 pmRNSTR-1 Maven
10th Oct 20255:20 pmRNSTR-1 Dowgate
9th Oct 20252:05 pmRNSTR-1 Spreadex
9th Oct 202511:04 amRNSTR-1 First Equity
8th Oct 20257:00 amRNSBreakthrough Launch Agreement
1st Oct 20252:08 pmRNS-RInterim Results 2025 Online Presentation
30th Sep 20257:00 amRNSInterim Results 2025
15th Sep 20256:07 pmRNSTR-1 Dowgate
12th Sep 20251:03 pmRNSTR-1 Dowgate
5th Aug 202512:13 pmRNSTR-1 First Equity
7th Jul 20252:33 pmRNSTR-1 Spreadex
19th Jun 20251:46 pmRNSResult of AGM
5th Jun 202510:11 amRNSCorrection - Application for Block Listing
4th Jun 202510:00 amRNSApplication for Block Listing
29th May 20252:43 pmRNSTR-1 Spreadex
28th May 20253:32 pmRNSTR-1 First Equity
28th May 20252:31 pmRNSTR-1 Spreadex
27th May 20252:37 pmRNSNotice of AGM and Posting of Annual Report
20th May 20257:00 amRNSFull Year Results 2024 and Trading Update
9th May 202511:08 amRNSTR-1 Spreadex
7th May 20257:00 amRNSNotice of Results and Online Presentation
6th May 202510:10 amRNSTR-1 Maven Capital
2nd May 20254:00 pmRNSTR-1 Spreadex
1st May 20254:35 pmRNSTR-1 - First Equity
31st Mar 20257:00 amRNSGrant of Options
7th Mar 202512:56 pmRNSTR-1 Spreadex
17th Feb 20252:18 pmRNSTR-1 Spreadex
17th Feb 202511:07 amRNSTR-1 First Equity
13th Feb 202512:05 pmRNSTR-1 Spreadex
13th Feb 202510:21 amRNSTR-1 First Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.